BioNTech
- Country
- 🇩🇪Germany
- Ownership
- Public
- Employees
- 6.1K
- Market Cap
- $20.7B
- Website
- http://www.biontech.de
- Introduction
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in M...
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 184
- Registration Number
- NCT04526899
- Locations
- 🇺🇸
University of California, San Francisco: Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇮🇹Azienda ospedaliera universitaria Bologna, Bologna, Italy
🇮🇹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 144
- Registration Number
- NCT04523571
- Locations
- 🇨🇳
Jiangsu Provincial Center for Disease Control and Prevention, Taizhou, Jiangsu, China
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 327
- Registration Number
- NCT04486378
- Locations
- 🇺🇸
Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Canada
🇺🇸Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 62
- Registration Number
- NCT04455620
- Locations
- 🇺🇸
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 75
- Registration Number
- NCT04382898
- Locations
- 🇬🇧
Cancer Research UK Cambridge Centre, Cambridge, United Kingdom
🇬🇧University of Glasgow, Beatson WoS Cancer Centre, Glasgow, United Kingdom
🇺🇸University of Miami Hospital & Clinics /Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 512
- Registration Number
- NCT04380701
- Locations
- 🇩🇪
Universitäts Klinikum, Heidelberg, Germany
🇩🇪Contract Research Organization, Mannheim, Germany
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
- Conditions
- Interventions
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 47079
- Registration Number
- NCT04368728
- Locations
- 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Lynn Institute of Norman, Norman, Oklahoma, United States
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
- Conditions
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 55
- Registration Number
- NCT04101357
- Locations
- 🇩🇪
University Medical Center Hamburg-Eppendorf - (Recruiting only for part 1B and part 2), Hamburg, Germany
🇩🇪Universitaetsklinikum Koeln - (Recruiting only for part 1B and part 2), Koeln, Germany
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 119
- Registration Number
- NCT02410733
- Locations
- 🇩🇪
Johann Wolfgang Goethe Universität Frankfurt, Klinik für Dermatologie, Venerologie und Allergologie, Frankfurt, Germany
🇩🇪Universitätsmedizin Mannheim, Klinik für Dermatologie, Venerologie und Allergologie, Mannheim, Germany
🇩🇪Universitätsmedizin Mainz, Hautklinik und Poliklinik, Mainz, Germany
RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID
- Conditions
- Interventions
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 42
- Registration Number
- NCT02316457
- Locations
- 🇩🇪
Johannes Gutenberg University, Mainz, RLP, Germany
🇩🇪Dr. Horst Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany
🇩🇪National Center for Tumor Diseases (NCT), Heidelberg, Germany